Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 11Neuroblastoma 7Lymphoma 7Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Leukemia 3Ganglioneuroblastoma 3Waldenstrom Macroglobulinemia 2Sarcoma, Ewing 2Preleukemia 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphatic Diseases 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

Radiotherapy 38Temozolomide 27Vincristine 15Chemotherapy, Adjuvant 11Carboplatin 11Filgrastim 10Granulocyte Colony-Stimulating Factor 9Etoposide 9Cyclophosphamide 9Lomustine 8Carmustine 7Cisplatin 6Peripheral Blood Stem Cell Transplantation 5etoposide phosphate 4Thiotepa 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Procarbazine 4Neoadjuvant Therapy 4Irinotecan 4Immunohistochemistry 4Gene Expression Profiling 4Topotecan 3Radiosurgery 3Radiation 3lonafarnib 2Psychiatric Rehabilitation 2Microarray Analysis 2Methotrexate 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Central Nervous System Neoplasms × Melphalan × Clear all
NCT00002594 2014-07-24

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Children's Oncology Group

Phase 2 Completed
31 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡